Literature DB >> 18548220

[Diagnostics and therapy of chronic hepatitis B and C].

J Wiegand1, J Mössner, H L Tillmann.   

Abstract

Therapy of chronic hepatitis B (HBV) und C (HCV) virus infection has continuously improved over the last years by the invention of new therapeutic agents for HBV, greater individualization for HCV and more sensitive tests for viral nucleic acids. Prognosis and therapeutic success rates have improved, however, more and more response predicting factors have to be considered prior to and during antiviral treatment to adjust therapy on an individual basis. Thus, in 2007 the German National Treatment Guidelines for HBV infection have been revised. A similar update is planned for chronic HCV infection in the year 2008. This review summarizes recommendations of the German National Hepatitis B Treatment Guidelines and shows current trends in the management of chronic hepatitis C which will be included in the future revised guidelines for hepatitis C. Since treatment of both infections will be characterized by a growing complexity, therapy should only be performed by internists with special experience in hepatology who are able to create individual concepts within evidenced-based treatment guidelines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18548220     DOI: 10.1007/s00108-008-2146-4

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  43 in total

Review 1.  [Standard treatment of acute and chronic hepatitis C].

Authors:  S Zeuzem
Journal:  Z Gastroenterol       Date:  2004-08       Impact factor: 2.000

2.  Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

Authors:  José M Sánchez-Tapias; Moisés Diago; Pedro Escartín; Jaime Enríquez; Manuel Romero-Gómez; Rafael Bárcena; Javier Crespo; Raúl Andrade; Eva Martínez-Bauer; Ramón Pérez; Milagros Testillano; Ramón Planas; Ricard Solá; Manuel García-Bengoechea; Javier Garcia-Samaniego; Miguel Muñoz-Sánchez; Ricardo Moreno-Otero
Journal:  Gastroenterology       Date:  2006-08       Impact factor: 22.682

3.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

4.  Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study.

Authors:  Olav Dalgard; Kristian Bjøro; Kjell Block Hellum; Bjørn Myrvang; Ståle Ritland; Kjell Skaug; Nils Raknerud; Helge Bell
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

5.  Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

Authors:  Thomas Berg; Michael von Wagner; Samer Nasser; Christoph Sarrazin; Tobias Heintges; Tilman Gerlach; Peter Buggisch; Tobias Goeser; Jens Rasenack; Gerd R Pape; Wolfgang E Schmidt; Birgit Kallinowski; Hartwig Klinker; Ulrich Spengler; Peter Martus; Ulrich Alshuth; Stefan Zeuzem
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

6.  Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

Authors:  Gary L Davis; John B Wong; John G McHutchison; Michael P Manns; Joann Harvey; Janice Albrecht
Journal:  Hepatology       Date:  2003-09       Impact factor: 17.425

7.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

Authors:  John G McHutchison; Michael Manns; Keyur Patel; Thierry Poynard; Karen L Lindsay; Christian Trepo; Jules Dienstag; William M Lee; Carmen Mak; Jean-Jacques Garaud; Janice K Albrecht
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

8.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Authors:  Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391

9.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

Authors:  C L Lai; R N Chien; N W Leung; T T Chang; R Guan; D I Tai; K Y Ng; P C Wu; J C Dent; J Barber; S L Stephenson; D F Gray
Journal:  N Engl J Med       Date:  1998-07-09       Impact factor: 91.245

10.  Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

Authors:  Stefan Zeuzem; Rolf Hultcrantz; Marc Bourliere; Tobias Goeser; Patrick Marcellin; Jose Sanchez-Tapias; Christoph Sarrazin; Joann Harvey; Clifford Brass; Janice Albrecht
Journal:  J Hepatol       Date:  2004-06       Impact factor: 25.083

View more
  1 in total

1.  [Interferon-alfa induced reactivation of sarcoidosis in a patient with chronic hepatitis C].

Authors:  I Mederacke; K Wursthorn; H Ho; M P Manns; H Wedemeyer
Journal:  Internist (Berl)       Date:  2010-04       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.